TABLE 1.
Model | Schwann cell source | Outcomes | Notes |
Rat sciatic nerve defect with an 8 mm gap | Autologous | Extensive peripheral nerve regeneration and myelination | • A strong immune reaction occurred when seeding with heterologous Schwann cells; • Seeding density of Schwann cells should be considered (Guenard et al., 1992) |
Sciatic nerve defect with a 5 mm gap in immune-deficient rats | Allogeneic, from human nerves | Promotion of axonal regeneration and myelination | Repair outcomes were better than the channels with Matrigel solution alone (Levi et al., 1994) |
Human sciatic nerve defect with a 7.5 cm gap | Autologous | Proximal sensory recovery, including neuropathic pain, and motor function recovery in the common peroneal and tibial distribution | The patient suffered complete transection of sciatic nerves by a boat propeller injury (Levi et al., 2016) |
Human sciatic nerve defect with a 5 cm gap | Autologous | Recovery of complete motor function and partial sensation in the tibial distribution | The patient suffered partial damage of the tibial division of sciatic nerves by a gun wound to the leg (Gersey et al., 2017) |
Mouse sciatic nerve crush | Allogeneic, from human skin | Promotion of axonal regrowth and myelination | • Adult human skin-derived Schwann cells were similar to human nerve-derived Schwann cells in genetical and phenotypical characterization; • Highly accessible source of autologous skin-derived Schwann cells was a substitute for nerve-derived Schwann cells for injured nerve repair (Stratton et al., 2017) |
Rat sciatic nerve defect with a 10 mm gap | Allogeneic, from neonatal rat sciatic nerves | Improvement in axonal regeneration | • The quantity of regenerated axons was less than that induced by treatment with syngeneic Schwann cells; • Immune response occurred at 6 weeks post-transplantation in the absence of immunosuppressive therapy (Mosahebi et al., 2002) |
Rat sciatic nerve defect with a 20 mm gap (Hoben et al., 2015), 10 mm gap (Sun et al., 2009) and 14 mm gap (Santosa et al., 2013) | Allogeneic, from neonatal (Sun et al., 2009; Hoben et al., 2015)/adult (Santosa et al., 2013) rat sciatic nerves | Improvement in axonal regeneration (Sun et al., 2009; Santosa et al., 2013; Hoben et al., 2015) and myelination (Sun et al., 2009) | • Acellular nerve allografts combined with allogeneic Schwann cells obtained the same outcomes as the isograft group (Hoben et al., 2015); • Adding vascular endothelial growth factor alone (Hoben et al., 2015) or Schwann cells overexpressing glial cell-derived neurotrophic factor (Santosa et al., 2013) in acellular nerve allografts had reduced effects on improving axonal regeneration |
Rat sciatic nerve injury with a 3 cm gap | Autologous, from the proximal stump neuroma | Regenerative fibers crossing the entire distance but no motor and poor sensory function recovery | It is challenging to regenerate axons with a 3 cm gap defect with only grafts (Aszmann et al., 2008) |
Primate ulnar nerve defect with a 6 cm gap | Autologous, from the sural nerve fascicles | Low immune response and significant regeneration | Cold-preserved allografts combined with autologous Schwann cells was a potentially safe and effective alternative to autografts (Hess et al., 2007) |
Rabbit peroneal nerve defect with a 6 cm gap | Autologous, from the contralateral peroneal nerve | Excellent growth of axons targeting the distal end | Autologous Schwann cells break the limit of nerve regeneration by an empty autogenous venous nerve conduit (Strauch et al., 2001) |
Rat sciatic nerve defect with a 10 mm gap (Mosahebi et al., 2002) and 1 cm gap (Bryan et al., 2000; Tohill et al., 2004; di Summa et al., 2011) | Allogeneic, from rat sciatic nerves | Improvements in axonal regrowth and fiber myelination | Combination with allogeneic Schwann cells obtained better outcomes in synthetic grafts, such as polyhydroxybutyrate conduits (Mosahebi et al., 2002; Tohill et al., 2004), fibrin conduits (di Summa et al., 2011) and poly (lactic-co-glycolic) acid conduits (Bryan et al., 2000) |